Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

99.53 +0.85 (+0.86%)
Streaming Delayed Price Updated: 10:39 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Thera

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Expert Ratings for Axsome Therapeutics
Via Benzinga
Baidu To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Monday
Keybanc boosted the price target for Camping World Holdings, Inc. (NYSE: CWH) from $28 to $36. Keybanc analyst Noah Zatzkin maintained an Overweight rating. Camping World shares rose 1.4% to $32.04 in... 
Via Benzinga
Got $500? 3 Growth Stocks to Buy That Could Double Your Money
There's no guarantee these stocks will deliver 2x returns over the next few years, but their prospects look good. 
Via The Motley Fool
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Why Shares of Axsome Therapeutics Fell Wednesday
The biopharmaceutical company announced a $225 million stock sale. 
Via The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
These companies are coming into their own. 
Via The Motley Fool
Where Will Axsome Therapeutics Be in 3 Years?
The stock soared more than 100% last year. 
Via The Motley Fool
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
5 Top Stocks for July
This basket of stocks has it all, including growth, dividend income, and value. 
Via The Motley Fool
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market. 
Via Benzinga
Why Is Xponential Fitness (XPOF) Stock Up 19% Today?
Xponential Fitness (XPOF) stock is climbing higher on Wednesday as the company strikes back against a short report from Fuzzy Panda Research. 
Via InvestorPlace
Why Is Axsome Therapeutics (AXSM) Stock Down 10% Today?
Axsome Therapeutics (AXSM) stock is heading lower on Wednesday as investors react to the company pricing a public share offering. 
Via InvestorPlace
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
From Axsome Therapeutics, Inc.
Via GlobeNewswire
As the Bull Roars, Shareholders Hate How These 2 Companies Are Selling Their Stock
Markets could have a tough time building on gains from Tuesday. 
Via The Motley Fool
This Stock Crushed the Market Last Year. Here's Why It Could Do That Again.
This small biotech could become much bigger in just a few years. 
Via The Motley Fool
Is Axsome Therapeutics Stock a Screaming Buy?
The biotech could be staring down an enormous commercial opportunity. 
Via The Motley Fool
Why Axsome Therapeutics Stock Is Rising Today
Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares are trading higher Wednesday following a recent corporate presentation. 
Via Benzinga
Axsome Therapeutics Stock Is Moving Lower: What's Going On?
Axsome Therapeutics Inc (NASDAQ: AXSM) shares are trading lower Wednesday after the company proposed a public offering of common stock. 
Via Benzinga
The Best Stocks to Invest $20,000 in Right Now
You can invest in these companies with $20,000 -- or even a lot less. 
Via The Motley Fool
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 Low-Priced Stocks That Could Make You Richer
These two low-priced healthcare stocks could skyrocket within the next 12 months. 
Via The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
They're not monsters now -- but just give them some time. 
Via The Motley Fool
Analyst Expectations for Axsome Therapeutics's Future
Via Benzinga
3 Biotech Stocks to Buy as Companies Ink Major Deals
Pharmaceutical and biotech companies will soon face generic competition, creating big opportunity for these top biotech stocks to buy. 
Via InvestorPlace
Does an $11.5 Billion Opportunity Make This Growth Stock a Buy Now?
Soaring sales of a new depression treatment could be just the tip of the iceberg for Axsome Therapeutics. 
Via The Motley Fool
Stock Market Rally Runs Through Hawkish Fed; Adobe, Lennar, Oracle, UnitedHealth In Focus: Weekly Review
Stocks kept powering higher despite, but the Nasdaq is looking extended. 
Via Investor's Business Daily
Axsome Therapeutics Expects Up To $11.5 Billion In Peak Sales, Wallops Analysts' Forecasts
The company's biggest products treats depression and could be used in other conditions. 
Via Investor's Business Daily
3 No-Brainer Stocks to Buy in June
These biopharma stocks could be big winners. 
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
You don't need a fortune to start investing. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.